Across TCGA pan-cancer cohorts, TMEM211 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TMEM211 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM211 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM211 expression acts as an unfavorable survival marker.

LIHC are the cancer types where TMEM211 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: TMEM211 tumor-vs-normal RNA expression · all TMEM211 data types